NCT03255070View on ClinicalTrials.gov

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

PHASE1CompletedINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

March 20, 2018

Primary Completion Date

September 13, 2023

Study Completion Date

October 18, 2023

Conditions

Breast NeoplasmsGastric NeoplasmSolid Tumors

Interventions

DRUG

ARX788

An antibody drug conjugate

Trial Locations (12)

2640

Research Site, East Albury

Research Site, North Sydney

3168

Monash Health, Clayton

3199

Research Site, Frankston

4101

Mater Misericordiae Limited, South Brisbane

4102

Princess Alexandria Hospital, Woolloongabba

6009

Research Site, Nedlands

44195

Cleveland Clinic, Cleveland

63110

Washington University School of Medicine, St Louis

75246

Baylor Sammons Cancer Center, Dallas

90033

USC Norris Cancer Hospital, Los Angeles

90095

UCLA Hematology-Oncology, Santa Monica

All Listed Sponsors

lead

Ambrx, Inc.

INDUSTRY

NCT03255070 - A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) | Biotech Hunter | Biotech Hunter